Dec 29, 2016 • 7:30 am EST Corbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis
Nov 29, 2016 • 7:30 am EST Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
Nov 14, 2016 • 6:30 am EST Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis
Nov 10, 2016 • 4:05 pm EST Corbus Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update
Oct 18, 2016 • 7:00 am EDT Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Oct 13, 2016 • 7:30 am EDT Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis
Sep 28, 2016 • 7:30 am EDT Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Sep 12, 2016 • 7:05 am EDT Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis